Analysts expect Galmed Pharmaceuticals Ltd. to report revenue of 0.00 for Q3 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q4 24, came in at 1.64 M.
| Metric | Q3 23 | Q4 23 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 1.64 M | - | - | - | - | - | - | ||||||||||||||||||
| High Estimate | 0.00 | 0.00 | - | 1.71 M | 1.67 M | 1.51 M | 1.34 M | 1.45 M | 1.43 M | ||||||||||||||||||
| Low Estimate | 0.00 | 0.00 | - | 1.47 M | 1.38 M | 1.40 M | 1.18 M | 1.22 M | 1.23 M | ||||||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | - | 1.59 M | 1.53 M | 1.45 M | 1.26 M | 1.34 M | 1.33 M |
Analysts expect Galmed Pharmaceuticals Ltd. to report earnings per share of -32.45 for Q4 23, against a range of -33.55 to -31.35. The most recent reported quarter, Q4 25, came in at -6.40, a 64.9% miss against the -3.88 consensus.
| Metric | Q3 23 | Q4 23 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -25.92 | - | -15.52 | -4.96 | -5.04 | -2.64 | -6.40 | - | - | - | - | - | - | - | |||||||||||||
| High Estimate | -28.58 | -31.35 | - | -6.19 | -5.83 | -4.10 | -3.55 | -2.74 | -2.63 | -2.80 | -2.97 | -0.49 | -1.71 | -2.40 | |||||||||||||
| Low Estimate | -32.58 | -33.55 | - | -7.15 | -6.85 | -5.00 | -4.21 | -2.92 | -3.19 | -3.18 | -3.61 | -0.59 | -1.87 | -2.58 | |||||||||||||
| Consensus Estimate | -30.58 | -32.45 | - | -6.67 | -6.34 | -4.55 | -3.88 | -2.83 | -2.91 | -2.99 | -3.29 | -0.54 | -1.79 | -2.49 |